1
Orphan Designations
0 approved, 1 designated
0
FDA Approvals
1
Active Trials
200 recruiting
3
Rare Diseases
across 6 areas
0
News (30d)
Quiet
Avenzoar Pharmaceuticals, Inc. is a company with 1 orphan drug designation across 3 rare diseases. Active clinical trials in 1 indication. 1 active policy bill affects their portfolio.
Disease-by-disease pipeline progression from orphan designation through clinical trials to FDA approval.
Source: FDA Orphan Drug Designations, ClinicalTrials.gov, Drugs@FDA
| Disease | Drug(s) | Stage |
|---|---|---|
| breast cancer | - | Des.TrialAppr. |
| malignant pancreatic neoplasm | metavert, N-hydroxy-4-(5-((4-methoxyphenyl)amino)-1,3,4-oxadiazol-2-yl)benzamide | Des.TrialAppr. |
| ovarian cancer | - | Des.TrialAppr. |
0% of portfolio targets high unmet need diseases
71
overlap in 2+ diseases
0/3
candidate diseases
0
avg importance: 0
1
affecting portfolio
0% of portfolio targets high unmet need diseases
71
overlap in 2+ diseases
0/3
candidate diseases
0
avg importance: 0
1
affecting portfolio